Is there a medical need to explore the clinical use of insulin-like growth factor I?

Martin O. Savage, Cecilia Camacho-Hübner, David B. Dunger, Michael B. Ranke, Richard J.M. Ross, Ron G. Rosenfeld

Research output: Contribution to journalReview articlepeer-review

14 Scopus citations


Cloning of the insulin-like growth factor I (IGF-I) gene led to the development in 1987 of recombinant IGF-I available for clinical use. Trials were started targeting endocrine, metabolic and neurological disorders, and beneficial results have been demonstrated in IGF-I deficiency states caused by IGF-I gene deletion and growth hormone (GH) receptor deficiency, type 1 and type 2 diabetes mellitus, and severe insulin resistance syndromes. Results of equivocal benefit have also been reported in osteoporosis and amyotrophic lateral sclerosis. Recent encouraging data using the IGF-I-IGF-binding protein 3 (IGFBP-3) complex in diabetes mellitus suggest that this preparation may eventually replace recombinant free IGF-I. The lack of an established therapeutic indication for IGF-I has resulted in its supplies being severely limited. It will probably be decided during the next decade whether use of IGF-I or the IGF-I-IGFBP-3 complex becomes firmly established as an accepted endocrine therapy.

Original languageEnglish (US)
Pages (from-to)S65-S69
JournalGrowth Hormone and IGF Research
Issue numberSUPPL. 1
StatePublished - 2001


  • Amyotrophic lateral sclerosis
  • Diabetes mellitus
  • Growth hormone receptor deficiency
  • Insulin resistance
  • Insulin-like growth factor I
  • Osteoporosis

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology


Dive into the research topics of 'Is there a medical need to explore the clinical use of insulin-like growth factor I?'. Together they form a unique fingerprint.

Cite this